RS67911B1 - C5ar1 inhibitori za lečenje reakcija preosetljivosti na taksane - Google Patents

C5ar1 inhibitori za lečenje reakcija preosetljivosti na taksane

Info

Publication number
RS67911B1
RS67911B1 RS20260336A RSP20260336A RS67911B1 RS 67911 B1 RS67911 B1 RS 67911B1 RS 20260336 A RS20260336 A RS 20260336A RS P20260336 A RSP20260336 A RS P20260336A RS 67911 B1 RS67911 B1 RS 67911B1
Authority
RS
Serbia
Prior art keywords
phenyl
c5ar1
ethyl
group
alkyl
Prior art date
Application number
RS20260336A
Other languages
English (en)
Serbian (sr)
Inventor
Marcello Allegretti
Andrea Aramini
Piergiorgio Amendola
Laura Brandolini
Maria Candida Cesta
Anna Sirico
Original Assignee
Dompe Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP21163292.2A external-priority patent/EP4059497A1/en
Application filed by Dompe Farm Spa filed Critical Dompe Farm Spa
Publication of RS67911B1 publication Critical patent/RS67911B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RS20260336A 2021-03-17 2022-03-17 C5ar1 inhibitori za lečenje reakcija preosetljivosti na taksane RS67911B1 (sr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP21163292.2A EP4059497A1 (en) 2021-03-17 2021-03-17 C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
EP21217382 2021-12-23
EP22716203.9A EP4308114B1 (en) 2021-03-17 2022-03-17 C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
PCT/EP2022/057007 WO2022195017A1 (en) 2021-03-17 2022-03-17 C5ar1 inhibitors for treating hypersensitivity reactions to taxanes

Publications (1)

Publication Number Publication Date
RS67911B1 true RS67911B1 (sr) 2026-04-30

Family

ID=81307212

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20260336A RS67911B1 (sr) 2021-03-17 2022-03-17 C5ar1 inhibitori za lečenje reakcija preosetljivosti na taksane

Country Status (14)

Country Link
US (1) US20240180888A1 (enExample)
EP (1) EP4308114B1 (enExample)
JP (1) JP2024512472A (enExample)
BR (1) BR112023018826A2 (enExample)
CA (1) CA3212816A1 (enExample)
DK (1) DK4308114T3 (enExample)
FI (1) FI4308114T3 (enExample)
HR (1) HRP20260351T1 (enExample)
IL (1) IL305727A (enExample)
LT (1) LT4308114T (enExample)
PL (1) PL4308114T3 (enExample)
RS (1) RS67911B1 (enExample)
SM (1) SMT202600118T1 (enExample)
WO (1) WO2022195017A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202543631A (zh) * 2024-03-14 2025-11-16 美商凡況生化公司 嗒嗪酮ｃ５ａｒ１拮抗劑及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053811A1 (en) * 1997-05-27 1998-12-03 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
WO1999022759A1 (en) * 1997-10-31 1999-05-14 Walter Reed Army Institute Of Research Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules
MXPA02004164A (es) * 1999-10-27 2002-10-17 Baker Norton Pharma Metodo y composiciones para administrar taxanos por via oral a pacientes humanos.
RS55192B1 (sr) 2005-11-24 2017-01-31 Dompé Farm S P A Derivati (r)-arilkilamina i farmaceutske kompozicije koje ih sadrže
EP3498269A1 (en) * 2017-12-12 2019-06-19 Dompé farmaceutici S.p.A. C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain

Also Published As

Publication number Publication date
WO2022195017A1 (en) 2022-09-22
SMT202600118T1 (it) 2026-05-12
FI4308114T3 (fi) 2026-03-25
BR112023018826A2 (pt) 2024-03-12
LT4308114T (lt) 2026-03-25
EP4308114B1 (en) 2026-02-11
HRP20260351T1 (hr) 2026-04-24
EP4308114A1 (en) 2024-01-24
PL4308114T3 (pl) 2026-05-04
CA3212816A1 (en) 2022-09-22
US20240180888A1 (en) 2024-06-06
DK4308114T3 (da) 2026-03-23
JP2024512472A (ja) 2024-03-19
IL305727A (en) 2023-11-01

Similar Documents

Publication Publication Date Title
RU2236220C2 (ru) Аналоги бензимидазола в качестве понижающих регуляторов ige
Dueñas-González et al. The prince and the pauper. A tale of anticancer targeted agents
JP2018188478A (ja) 肝疾患を処置する方法
US20040248983A1 (en) N-arylphenylacetamide derivatives and medicinal compositions containing the same
US20090047278A1 (en) Novel Combinational Use of Sulfonamide Compound
Liu et al. Design and synthesis of marine phidianidine derivatives as potential immunosuppressive agents
CN116173014A (zh) 用阿曲生坦治疗IgA肾病的方法
CN113227093A (zh) 结晶螺环化合物、包含该化合物的剂型、用于疾病治疗的方法和再结晶方法
JP2010534685A (ja) チロシンキナーゼ阻害剤およびインテグリンα５β１（ＣＤ４９Ｅ）に対する抗体を含む薬学的な組み合わせ
EP4059497A1 (en) C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
CA2952016A1 (en) Cyp2j2 antagonists in the treatment of pain
EP1771162B1 (en) Capsaicin inhibitors for the treatment of obesity-related disorders
EP4308114B1 (en) C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
KR20100135700A (ko) 지방성 간 질환의 치료용 의약 조성물
CN109700794B (zh) 腙结构类型雄激素受体拮抗剂及其应用
Chatzipieris et al. Unlocking Novel Therapeutic Potential of Angiotensin II Receptor Blockers
RU2857199C2 (ru) Предотвращение и лечение реакций гиперчувствительности к таксанам
TWI594991B (zh) 第一型類升糖素肽調節子及其用途
CN117337176A (zh) 用于治疗对紫杉烷类的超敏反应的c5ar1抑制剂
JP2005511639A (ja) 虚血性疾患の治療用ドパミン再取り込み阻害活性を有するトロパン誘導体
TWI817307B (zh) 多扎格列艾汀（ｄｏｒｚａｇｌｉａｔｉｎ）和胰高血糖素樣肽-１類似物的藥物組成物
CN1652774A (zh) 缬沙坦或其代谢物用于抑制血小板凝集的用途
JP2023145581A (ja) インターロイキン－２３受容体のペプチド阻害剤の組成物
US20220288034A1 (en) Method of reducing aberrant immune response or risk of progression in covid-19
EP4008325A1 (en) Cxcl8 inhibitors for use in the treatment of covid-19